Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 2,945 shares of the business's stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $33.11, for a total transaction of $97,508.95. Following the completion of the transaction, the chief executive officer now directly owns 479,851 shares of the company's stock, valued at approximately $15,887,866.61. This represents a 0.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Ying Du also recently made the following trade(s):
- On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The shares were sold at an average price of $35.89, for a total value of $208,449.12.
- On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $32.44, for a total value of $1,622,000.00.
- On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00.
Zai Lab Stock Up 21.5 %
Shares of ZLAB stock traded up $5.22 during trading hours on Friday, hitting $29.54. 3,044,626 shares of the company's stock traded hands, compared to its average volume of 822,235. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of -10.66 and a beta of 1.09. The stock's fifty day simple moving average is $32.74 and its two-hundred day simple moving average is $29.07. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $39.77.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The company had revenue of $109.07 million during the quarter, compared to the consensus estimate of $110.15 million. On average, equities analysts forecast that Zai Lab Limited will post -2.58 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in shares of Zai Lab during the fourth quarter valued at approximately $29,000. Pictet Asset Management Holding SA purchased a new position in shares of Zai Lab in the fourth quarter worth $31,000. Barclays PLC raised its stake in shares of Zai Lab by 337.6% in the fourth quarter. Barclays PLC now owns 3,702 shares of the company's stock worth $97,000 after purchasing an additional 2,856 shares during the last quarter. US Bancorp DE boosted its position in shares of Zai Lab by 1,671.9% during the fourth quarter. US Bancorp DE now owns 5,865 shares of the company's stock valued at $154,000 after buying an additional 5,534 shares during the last quarter. Finally, Jasper Ridge Partners L.P. bought a new stake in Zai Lab in the 4th quarter worth about $210,000. 41.65% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
ZLAB has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research report on Thursday, March 13th. Bank of America reissued a "neutral" rating and issued a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Scotiabank assumed coverage on Zai Lab in a research report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th.
Check Out Our Latest Analysis on ZLAB
About Zai Lab
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Featured Stories
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
